Literature DB >> 18160997

Polymorphisms of promoter and coding regions of the arylamine N-acetyltransferase 2 (NAT2) gene in the Indonesian population: proposal for a new nomenclature.

Rika Yuliwulandari1,2, Qomariyah Sachrowardi2, Nao Nishida1, Miwa Takasu1, Lilian Batubara2, Tri Panjiasih Susmiarsih2, Jecti Teguh Rochani2, Riyani Wikaningrum2, Risa Miyashita1, Taku Miyagawa1, Abdul Salam Mudzakir Sofro2, Katsushi Tokunaga3.   

Abstract

Polymorphisms of arylamine N-acetyltransferase 2 (NAT2) are reportedly associated with the risk of drug toxicities and development of various diseases. The present study examined NAT2 polymorphisms in both promoter and coding regions in the Indonesian population using PCR direct sequencing. The promoter and coding regions of NAT2 displayed 23 polymorphisms/variations, including eight new ones. Seven haplotypes in the promoter region and six haplotypes in the coding region were inferred. The haplotypes in promoter and coding regions showed limited combinations, and 13 combined haplotypes were inferred. The most frequent haplotypes were U1 (38.9%), U2 (33.5%) in the promoter region and NAT2*4 (37.3%), NAT2*6A (36.8%) in the coding region. When converted to predicted phenotypes, the studied population comprised 65.4% rapid acetylators and 35.6% slow acetylators according to bimodal distribution. According to trimodal distribution, frequencies of predicted phenotypes were 13.6, 50.8 and 35.6% for rapid, intermediate and slow acetylators, respectively. Frequencies of NAT2 alleles for the Indonesian population resembled those of other Southeast Asian populations. We also propose a new NAT2 nomenclature composed of haplotypes in the promoter region and conventional NAT2 haplotypes in the coding region, symbolized by NAT2*4.U1, NAT2*4.U2, NAT2*4.U3, NAT2*4.U5, NAT2*4.U6, NAT2*4.U7, NAT2*6A.U1, NAT2*7B.U2, NAT2*7B.U3, NAT2*5B.U1, NAT2*5B.U4, NAT2*12A.U4 and NAT2*13.U1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18160997     DOI: 10.1007/s10038-007-0237-z

Source DB:  PubMed          Journal:  J Hum Genet        ISSN: 1434-5161            Impact factor:   3.172


  39 in total

1.  Complete sequencing of a genetic polymorphism in NAT2 in the Korean population.

Authors:  Soo-Youn Lee; Kyung-A Lee; Chang-Seok Ki; O Jung Kwon; Ho Joong Kim; Man Pyo Chung; Gee Young Suh; Jong-Won Kim
Journal:  Clin Chem       Date:  2002-05       Impact factor: 8.327

2.  Genotyping of the N-acetyltransferase2 polymorphism in the prediction of adverse drug reactions to isoniazid in Japanese patients.

Authors:  Masahiro Hiratsuka; Yukinaga Kishikawa; Yoh Takekuma; Masaki Matsuura; Kaori Narahara; Tomoko Inoue; Samar Ismail Hamdy; Naomi Endo; Junichi Goto; Michinao Mizugaki
Journal:  Drug Metab Pharmacokinet       Date:  2002       Impact factor: 3.614

3.  Polymorphic N-acetyltransferase (NAT2) genotyping of Emiratis.

Authors:  N M Woolhouse; M M Qureshi; S M Bastaki; M Patel; Y Abdulrazzaq; R A Bayoumi
Journal:  Pharmacogenetics       Date:  1997-02

4.  Discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects.

Authors:  Robert J Straka; R Todd Burkhardt; Nicholas P Lang; Kelly Z Hadsall; Michael Y Tsai
Journal:  J Clin Pharmacol       Date:  2006-07       Impact factor: 3.126

5.  Novel human N-acetyltransferase 2 alleles that differ in mechanism for slow acetylator phenotype.

Authors:  M A Leff; A J Fretland; M A Doll; D W Hein
Journal:  J Biol Chem       Date:  1999-12-03       Impact factor: 5.157

6.  Arylamine N-acetyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity.

Authors:  I Cascorbi; N Drakoulis; J Brockmöller; A Maurer; K Sperling; I Roots
Journal:  Am J Hum Genet       Date:  1995-09       Impact factor: 11.025

7.  The influence of various genotypes on the metabolic activity of NAT2 in a Chinese population.

Authors:  Bing Chen; Wei-Xia Zhang; Wei-Min Cai
Journal:  Eur J Clin Pharmacol       Date:  2006-03-29       Impact factor: 2.953

8.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans.

Authors:  M Blum; A Demierre; D M Grant; M Heim; U A Meyer
Journal:  Proc Natl Acad Sci U S A       Date:  1991-06-15       Impact factor: 11.205

9.  Identification of N-acetyltransferase 2 (NAT2) transcription start sites and quantitation of NAT2-specific mRNA in human tissues.

Authors:  Anwar Husain; Xiaoyan Zhang; Mark A Doll; J Christopher States; David F Barker; David W Hein
Journal:  Drug Metab Dispos       Date:  2007-02-07       Impact factor: 3.922

10.  Association of the diplotype configuration at the N-acetyltransferase 2 gene with adverse events with co-trimoxazole in Japanese patients with systemic lupus erythematosus.

Authors:  Makoto Soejima; Tomoko Sugiura; Yasushi Kawaguchi; Manabu Kawamoto; Yasuhiro Katsumata; Kae Takagi; Ayako Nakajima; Tadayuki Mitamura; Akio Mimori; Masako Hara; Naoyuki Kamatani
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

View more
  5 in total

1.  NAT2 variants are associated with drug-induced liver injury caused by anti-tuberculosis drugs in Indonesian patients with tuberculosis.

Authors:  Rika Yuliwulandari; Retno Wilujeng Susilowati; Britanto Dani Wicaksono; Kencono Viyati; Kinasih Prayuni; Intan Razari; Erna Kristin; Eva Sri Diana; Suci Setiawati; Aziza Ariyani; Surakameth Mahasirimongkol; Hideki Yanai; Taisei Mushiroda; Katsushi Tokunaga
Journal:  J Hum Genet       Date:  2016-02-25       Impact factor: 3.172

2.  Study of NAT2 gene polymorphisms in an Indian population: association with plasma isoniazid concentration in a cohort of tuberculosis patients.

Authors:  Neera Singh; Sudhisha Dubey; Saravanan Chinnaraj; Anil Golani; Anurupa Maitra
Journal:  Mol Diagn Ther       Date:  2009       Impact factor: 4.074

Review 3.  Structure/function evaluations of single nucleotide polymorphisms in human N-acetyltransferase 2.

Authors:  Jason M Walraven; Yu Zang; John O Trent; David W Hein
Journal:  Curr Drug Metab       Date:  2008-07       Impact factor: 3.731

Review 4.  N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine.

Authors:  David W Hein
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-04       Impact factor: 4.481

5.  NAT2 Gene Polymorphisms in Turkish Patients with Psoriasis Vulgaris.

Authors:  Recep Dursun; Hatice Gül Dursun; Ayşe Gül Zamani; Mahmut Selman Yıldırım; İlknur Çınar
Journal:  Biomed Res Int       Date:  2018-06-11       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.